ATE531390T1 - Interleukin-15-(il-15-)spezifische menschliche antikörper - Google Patents

Interleukin-15-(il-15-)spezifische menschliche antikörper

Info

Publication number
ATE531390T1
ATE531390T1 AT02796411T AT02796411T ATE531390T1 AT E531390 T1 ATE531390 T1 AT E531390T1 AT 02796411 T AT02796411 T AT 02796411T AT 02796411 T AT02796411 T AT 02796411T AT E531390 T1 ATE531390 T1 AT E531390T1
Authority
AT
Austria
Prior art keywords
human
antibodies
human antibodies
interleukin
specific human
Prior art date
Application number
AT02796411T
Other languages
English (en)
Inventor
De Winkel Jan Van
Dijk Marcus Van
Janine Schuurman
Arnout Gerritsen
Ole Baadsgaard
Original Assignee
Genmab As
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genmab As filed Critical Genmab As
Application granted granted Critical
Publication of ATE531390T1 publication Critical patent/ATE531390T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C07K16/244—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/32—Immunoglobulins specific features characterized by aspects of specificity or valency specific for a neo-epitope on a complex, e.g. antibody-antigen or ligand-receptor
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Oncology (AREA)
  • Rheumatology (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Dermatology (AREA)
  • AIDS & HIV (AREA)
  • Pain & Pain Management (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
AT02796411T 2001-08-23 2002-08-23 Interleukin-15-(il-15-)spezifische menschliche antikörper ATE531390T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US31473101P 2001-08-23 2001-08-23
PCT/US2002/026769 WO2003017935A2 (en) 2001-08-23 2002-08-23 Human antibodies specific for interleukin 15 (il-15)

Publications (1)

Publication Number Publication Date
ATE531390T1 true ATE531390T1 (de) 2011-11-15

Family

ID=23221192

Family Applications (1)

Application Number Title Priority Date Filing Date
AT02796411T ATE531390T1 (de) 2001-08-23 2002-08-23 Interleukin-15-(il-15-)spezifische menschliche antikörper

Country Status (24)

Country Link
US (1) US7153507B2 (de)
EP (1) EP1425389B1 (de)
JP (2) JP4359503B2 (de)
KR (1) KR100911951B1 (de)
CN (1) CN100557018C (de)
AT (1) ATE531390T1 (de)
AU (1) AU2002332628B2 (de)
BR (1) BR0212136A (de)
CA (1) CA2456648C (de)
CY (1) CY1112447T1 (de)
DK (1) DK1425389T3 (de)
EA (1) EA014802B1 (de)
ES (1) ES2375271T3 (de)
HU (1) HU229776B1 (de)
IL (2) IL160358A0 (de)
MX (1) MXPA04001486A (de)
NO (1) NO333152B1 (de)
NZ (1) NZ531211A (de)
PL (1) PL217752B1 (de)
PT (1) PT1425389E (de)
RS (1) RS51829B (de)
SI (1) SI1425389T1 (de)
WO (1) WO2003017935A2 (de)
ZA (1) ZA200401144B (de)

Families Citing this family (289)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2385745C (en) 2001-06-08 2015-02-17 Abbott Laboratories (Bermuda) Ltd. Methods of administering anti-tnf.alpha. antibodies
US7247304B2 (en) * 2001-08-23 2007-07-24 Genmab A/S Methods of treating using anti-IL-15 antibodies
US7329405B2 (en) 2001-08-23 2008-02-12 Genmab A/S Human antibodies specific for interleukin 15 (IL-15)
PL217752B1 (pl) 2001-08-23 2014-08-29 Genmab As Izolowane ludzkie przeciwciało monoklonalne wobec IL-15 lub jego fragment wiążący antygen i związane z nimi hybrydoma, kompozycja farmaceutyczna oraz zastosowania medyczne
GB0208817D0 (en) * 2002-04-17 2002-05-29 European Molecular Biology Lab Embl Method for producing monoclonal antibodies
CN1780856A (zh) * 2003-02-26 2006-05-31 根马布股份公司 白介素15(il－15)的特异性人抗体
NZ570709A (en) 2003-06-13 2010-04-30 Univ Pennsylvania Nucleic acid sequences encoding and compositions comprising IgE signal peptide and/or IL-15 and methods for using the same
US20050123542A1 (en) * 2003-11-06 2005-06-09 Genmab A/S Methods for treating disorders involving monocytes
NZ554520A (en) * 2004-10-22 2010-03-26 Amgen Inc Methods for refolding of recombinant antibodies
KR20070089186A (ko) * 2004-12-13 2007-08-30 사이토스 바이오테크놀로지 아게 Ｉｌ-15 항원 어레이 및 그 용도
AU2006246721B2 (en) 2005-05-16 2012-12-13 Abbvie Biotechnology Ltd Use of TNF inhibitor for treatment of erosive polyarthritis
ES2776657T3 (es) 2005-06-14 2020-07-31 Amgen Inc Formulaciones de proteínas autotamponantes
US20070190057A1 (en) * 2006-01-23 2007-08-16 Jian Wu Methods for modulating mannose content of recombinant proteins
WO2007120656A2 (en) * 2006-04-10 2007-10-25 Abbott Biotechnology Ltd. Uses and compositions for treatment of rheumatoid arthritis
US9605064B2 (en) 2006-04-10 2017-03-28 Abbvie Biotechnology Ltd Methods and compositions for treatment of skin disorders
US20080131374A1 (en) * 2006-04-19 2008-06-05 Medich John R Uses and compositions for treatment of rheumatoid arthritis
KR20090114443A (ko) 2007-02-09 2009-11-03 제넨테크, 인크. 항-Ｒｏｂｏ４ 항체 및 그의 용도
WO2008154543A2 (en) 2007-06-11 2008-12-18 Abbott Biotechnology Ltd. Methods for treating juvenile idiopathic arthritis
EP2197421A1 (de) * 2007-08-31 2010-06-23 Amgen, Inc Protein-formulierung in festem zustand
MX2010002683A (es) * 2007-09-14 2010-03-26 Amgen Inc Poblaciones de anticuerpos homogeneos.
WO2009043049A2 (en) * 2007-09-27 2009-04-02 Amgen Inc. Pharmaceutical formulations
WO2009064838A1 (en) 2007-11-15 2009-05-22 Amgen, Inc. Aqueous formulation of erythropoiesis stimulating protein stablised by antioxidants for parenteral administration
AR069501A1 (es) 2007-11-30 2010-01-27 Genentech Inc Anticuerpos anti- vegf (factor de crecimiento endotelial vascular)
EP2098536A1 (de) 2008-03-05 2009-09-09 4-Antibody AG Isolation und Identifikation antigen- oder ligandenspezifischer Bindungsproteine
US20100040630A1 (en) * 2008-03-24 2010-02-18 Aake Elden Methods and compositions for treating bone loss
CU23716A1 (es) 2008-09-30 2011-10-05 Ct Ingenieria Genetica Biotech Péptido antagonista de la actividad de la interleucina-15
UA109633C2 (uk) 2008-12-09 2015-09-25 Антитіло людини проти тканинного фактора
AR077595A1 (es) 2009-07-27 2011-09-07 Genentech Inc Tratamientos de combinacion
EP2473522B1 (de) 2009-09-02 2016-08-17 Genentech, Inc. Smoothened-mutant und verfahren zu seiner anwendung
MX344382B (es) 2009-10-23 2016-12-14 Amgen Inc * Adaptador de vial y sistema.
EP2509626B1 (de) 2009-12-11 2016-02-10 F.Hoffmann-La Roche Ag Anti-vegf-c-antikörper und verfahren zu ihrer verwendung
SG181834A1 (en) 2009-12-21 2012-07-30 Genentech Inc Antibody formulation
HUE026173T2 (en) 2010-06-07 2016-05-30 Amgen Inc pharmaceutical Pump
EP3613774A1 (de) 2010-06-09 2020-02-26 Genmab A/S Antikorper gegen menschliches cd38
AU2011267106B2 (en) 2010-06-15 2015-05-14 Genmab A/S Human antibody drug conjugates against tissue factor
EP2625197B1 (de) 2010-10-05 2016-06-29 Genentech, Inc. Smoothened-mutant und verfahren zu seiner anwendung
AU2012236573B2 (en) 2011-03-31 2016-06-02 Amgen Inc. Vial adapter and system
TR201905991T4 (tr) 2011-04-20 2019-05-21 Amgen Inc Oto enjektör aparatı.
CN102250243B (zh) * 2011-07-01 2013-08-28 华绍炳 抗白细胞介素-15抗体
PT2734538T (pt) * 2011-07-18 2018-08-02 Iba Gmbh Processo para corar, de forma reversível, uma célula-alvo
EP3045188B1 (de) 2011-10-14 2020-12-23 Amgen Inc. Injektor und verfahren zur montage
EP2922590B1 (de) 2012-11-21 2020-02-05 Amgen Inc. Arzneimittelabgabevorrichtung
ES2878749T3 (es) 2013-02-20 2021-11-19 Innate Pharma Un compuesto que se une específicamente a KIR3DL2 para el uso en el tratamiento de linfoma de células T periférico
MY199135A (en) 2013-03-13 2023-10-17 Genentech Inc Formulations with reduced oxidation
CA2904169C (en) 2013-03-13 2021-12-07 Genentech, Inc. Formulations with reduced oxidation
AR095398A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones con oxidación reducida
AR095399A1 (es) 2013-03-13 2015-10-14 Genentech Inc Formulaciones con oxidación reducida, método
CN105209069B (zh) 2013-03-13 2019-08-23 豪夫迈·罗氏有限公司 抗体配制剂
TWI614041B (zh) 2013-03-15 2018-02-11 安美基公司 用於注射器之匣盒
US10092703B2 (en) 2013-03-15 2018-10-09 Amgen Inc. Drug cassette, autoinjector, and autoinjector system
BR112015021993A8 (pt) 2013-03-15 2019-12-03 Genentech Inc polipeptídeo, métodos para sua produção, métodos para cultivo de uma célula, composição farmacêutica, kit, e meio de cultura celular
SG11201507417RA (en) 2013-03-15 2015-10-29 Amgen Inc Body contour adaptable autoinjector device
EP2976117B1 (de) 2013-03-22 2020-12-30 Amgen Inc. Injektor und verfahren zur montage
SI3049441T1 (sl) 2013-09-27 2020-03-31 F. Hoffmann-La Roche Ag Formulacije protiteles proti PD-L1
EP3957345B1 (de) 2013-10-24 2025-12-10 Amgen Inc. Arzneimittelabgabesystem mit temperaturempfindlicher steuerung
CA2920894C (en) 2013-10-24 2023-03-14 Amgen Inc. Injector and method of assembly
NZ760065A (en) 2013-12-17 2022-12-23 Genentech Inc Methods of treating cancers using pd-1 axis binding antagonists and taxanes
MX2016007885A (es) 2013-12-17 2017-01-11 Genentech Inc Metodos de tratamiento de cancer usando antagonistas de union del eje de pd-1 y un anticuerpo anti-cd20.
CA2934028A1 (en) 2013-12-17 2015-06-25 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
CA2937539A1 (en) 2014-02-04 2015-08-13 Genentech, Inc. Mutant smoothened and methods of using the same
US10994112B2 (en) 2014-02-05 2021-05-04 Amgen Inc. Drug delivery system with electromagnetic field generator
RU2016142476A (ru) 2014-03-31 2018-05-07 Дженентек, Инк. Комбинированная терапия, включающая антиангиогенезные агенты и агонисты, связывающие ох40
MX388536B (es) 2014-05-07 2025-03-20 Amgen Inc Autoinyector con elementos reductores del shock.
CN106470717B (zh) 2014-06-03 2020-09-11 安姆根有限公司 药物递送系统和使用方法
EP2963057A1 (de) 2014-07-02 2016-01-06 Calypso Biotech SA Antikörper zu IL-15
JP7072384B2 (ja) 2014-09-15 2022-05-20 ジェネンテック， インコーポレイテッド 抗体製剤
AU2015332557B2 (en) 2014-10-14 2020-05-14 Amgen Inc. Drug injection device with visual and audio indicators
MX388858B (es) 2014-10-23 2025-03-20 Amgen Inc Reducción de la viscosidad de formulaciones farmacéuticas
MX2017006320A (es) 2014-11-17 2017-08-10 Genentech Inc Terapia combinada que comprende agonistas de unión de ox40 y antagonistas de unión del eje de pd-1.
EP3848072A1 (de) 2014-12-19 2021-07-14 Amgen Inc. Medikamentenabgabevorrichtung mit näherungssensor
ES2785311T3 (es) 2014-12-19 2020-10-06 Amgen Inc Dispositivo de administración de fármacos con botón móvil o campo de interfaz de usuario
US10330683B2 (en) 2015-02-04 2019-06-25 Genentech, Inc. Mutant smoothened and methods of using the same
CA3069716C (en) 2015-02-17 2021-11-09 Amgen Inc. Drug delivery device with vacuum assisted securement and/or feedback
EP3261690B1 (de) 2015-02-27 2021-12-15 Amgen Inc. Arzneimittelabgabevorrichtung mit nadelschutzmechanismus mit abstimmbarem widerstandsschwellwert gegenüber der bewegung des nadelschutzes
IL256080B2 (en) 2015-06-17 2025-06-01 Genentech Inc Methods of treating locally advanced or metastatic breast cancers using pd-1 axis binding antagonists and taxanes
JOP20200312A1 (ar) 2015-06-26 2017-06-16 Novartis Ag الأجسام المضادة للعامل xi وطرق الاستخدام
TWI899515B (zh) 2015-08-04 2025-10-01 美商再生元醫藥公司 補充牛磺酸之細胞培養基及用法
MA42613A (fr) 2015-08-13 2018-06-20 Amgen Inc Filtration en profondeur chargée de protéines de liaison à un antigène
WO2017039786A1 (en) 2015-09-02 2017-03-09 Amgen Inc. Syringe assembly adapter for a syringe
WO2017100501A1 (en) 2015-12-09 2017-06-15 Amgen Inc. Auto-injector with signaling cap
EP3397243A1 (de) 2015-12-30 2018-11-07 H. Hoffnabb-La Roche Ag Verwendung von tryptophanderivaten für proteinformulierungen
IL299759A (en) 2015-12-30 2023-03-01 Genentech Inc Formulations with reduced polysorbate dissolution
US11154661B2 (en) 2016-01-06 2021-10-26 Amgen Inc. Auto-injector with signaling electronics
AR107303A1 (es) 2016-01-08 2018-04-18 Hoffmann La Roche Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
EP3411396A1 (de) 2016-02-04 2018-12-12 Curis, Inc. Smoothened-mutant und verfahren zur verwendung davon
WO2017160799A1 (en) 2016-03-15 2017-09-21 Amgen Inc. Reducing probability of glass breakage in drug delivery devices
MX2018010546A (es) 2016-03-15 2019-02-20 Chugai Pharmaceutical Co Ltd Metodos de tratamiento de cancer que usan antagonistas de union al eje de muerte programada 1 (pd-1) y anticuerpos anti glipicano 3 (gpc3).
WO2017189089A1 (en) 2016-04-29 2017-11-02 Amgen Inc. Drug delivery device with messaging label
US11389588B2 (en) 2016-05-02 2022-07-19 Amgen Inc. Syringe adapter and guide for filling an on-body injector
AU2017263558B2 (en) 2016-05-13 2022-12-22 Amgen Inc. Vial sleeve assembly
EP3458988B1 (de) 2016-05-16 2023-10-18 Amgen Inc. Datenverschlüsselung in medizinischen vorrichtungen mit eingeschränkter rechenfähigkeit
TW201802121A (zh) 2016-05-25 2018-01-16 諾華公司 抗因子XI/XIa抗體之逆轉結合劑及其用途
WO2017209899A1 (en) 2016-06-03 2017-12-07 Amgen Inc. Impact testing apparatuses and methods for drug delivery devices
US20180002417A1 (en) 2016-06-15 2018-01-04 Celimmune Llc Methods and Compositions for the Treatment of Celiac Disease, Non-Celiac Gluten Sensitivity, and Refractory Celiac Disease
WO2018004842A1 (en) 2016-07-01 2018-01-04 Amgen Inc. Drug delivery device having minimized risk of component fracture upon impact events
CN109476748B (zh) 2016-08-08 2023-05-23 豪夫迈·罗氏有限公司 用于癌症的治疗和诊断方法
US20190328965A1 (en) 2016-08-17 2019-10-31 Amgen Inc. Drug delivery device with placement detection
WO2018067987A1 (en) 2016-10-06 2018-04-12 Amgen Inc. Reduced viscosity protein pharmaceutical formulations
EP3528787B1 (de) * 2016-10-21 2026-01-07 Amgen Inc. Pharmazeutische formulierungen und verfahren zur herstellung davon
WO2018081234A1 (en) 2016-10-25 2018-05-03 Amgen Inc. On-body injector
PL3558369T3 (pl) * 2016-12-21 2025-06-23 Cephalon Llc Przeciwciała specyficznie wiążące się z ludzką il-15 i ich zastosowania
US11168147B2 (en) 2016-12-23 2021-11-09 Novartis Ag Factor XI antibodies and methods of use
JP2020503976A (ja) 2017-01-17 2020-02-06 アムジエン・インコーポレーテツド 注入デバイスならびに関連する使用および組立方法
MX2019009625A (es) 2017-02-17 2019-10-09 Amgen Inc Dispositivo de administracion de farmacos con trayectoria de flujo de fluido esteril y metodo relacionado de ensamblaje.
EP3582829A1 (de) 2017-02-17 2019-12-25 Amgen Inc. Einführmechanismus für eine arzneimittelabgabevorrichtung
JP7377596B2 (ja) 2017-02-22 2023-11-10 アムジエン・インコーポレーテツド 低粘度、高濃度エボロクマブ製剤及びそれらの製造方法
EP3592403B1 (de) 2017-03-06 2025-08-20 Amgen Inc. Wirkstofffreisetzungsvorrichtung mit aktivierungsverhinderungsfunktion
CA3052482A1 (en) 2017-03-07 2018-09-13 Amgen Inc. Needle insertion by overpressure
AU2018230486B2 (en) 2017-03-09 2023-05-11 Amgen Inc. Insertion mechanism for drug delivery device
CN118743804A (zh) 2017-03-28 2024-10-08 美国安进公司 柱塞杆和注射器组件系统以及方法
CA3061328A1 (en) 2017-04-24 2018-11-01 University Of Massachusetts Diagnosis and treatment of vitiligo
ES3036143T3 (en) 2017-04-28 2025-09-15 Amgen Inc N-acetylated and non-acetylated dipeptides containing arginine to reduce the viscosity of viscous compositions of therapeutic polypeptides
CA3066399A1 (en) 2017-06-08 2018-12-13 Amgen Inc. Torque driven drug delivery device
AU2018280054B2 (en) 2017-06-08 2023-07-13 Amgen Inc. Syringe assembly for a drug delivery device and method of assembly
AU2018288604B2 (en) 2017-06-22 2023-12-21 Amgen Inc. Device activation impact/shock reduction
MA49461A (fr) 2017-06-23 2020-04-29 Amgen Inc Dispositif électronique d'administration de médicament comprenant un bouchon activé par un ensemble commutateur
MA49562A (fr) 2017-07-14 2020-05-20 Amgen Inc Système d'insertion-rétractation d'aiguille présentant un système à ressort en double torsion
US11672733B2 (en) 2017-07-21 2023-06-13 Amgen Inc. Gas permeable sealing member for drug container and methods of assembly
JP2020528296A (ja) 2017-07-25 2020-09-24 アムジエン・インコーポレーテツド ギヤモジュールを有する薬物送達デバイス及び関連する組立方法
US11484648B2 (en) 2017-07-25 2022-11-01 Amgen Inc. Drug delivery device with container access system and related method of assembly
MX2020001171A (es) 2017-08-01 2020-03-12 Amgen Inc Sistemas y metodos para realizar un ensayo de glicanos en tiempo real de una muestra.
IL271499B2 (en) 2017-08-01 2024-12-01 Amgen Inc Systems and methods for real-time polypeptide sample preparation for mass spectrometry analysis
WO2019032482A2 (en) 2017-08-09 2019-02-14 Amgen Inc. HYDRAULIC-PNEUMATIC PRESSURE CHAMBER DELIVERY SYSTEM
WO2019036181A1 (en) 2017-08-18 2019-02-21 Amgen Inc. BODY INJECTOR WITH STERILE ADHESIVE PATCH
US11103636B2 (en) 2017-08-22 2021-08-31 Amgen Inc. Needle insertion mechanism for drug delivery device
ES2939292T3 (es) 2017-10-04 2023-04-20 Amgen Inc Adaptador de flujo para dispositivo de administración de fármacos
EP4257164A3 (de) 2017-10-06 2024-01-17 Amgen Inc. Arzneimittelabgabevorrichtung mit verriegelungsvorrichtung und zugehöriges montageverfahren
EP3694578B1 (de) 2017-10-09 2025-09-24 Amgen Inc. Arzneimittelabgabevorrichtung mit antriebsanordnung sowie zugehöriges verfahren zur montage
MA50528A (fr) 2017-11-03 2020-09-09 Amgen Inc Systèmes et approches pour stériliser un dispositif d'administration de médicament
US12053618B2 (en) 2017-11-06 2024-08-06 Amgen Inc. Fill-finish assemblies and related methods
WO2019089178A1 (en) 2017-11-06 2019-05-09 Amgen Inc. Drug delivery device with placement and flow sensing
IL319987A (en) 2017-11-10 2025-06-01 Amgen Inc Plungers for drug delivery devices
SG11202003004RA (en) 2017-11-16 2020-04-29 Amgen Inc Door latch mechanism for drug delivery device
JP7747438B2 (ja) 2017-11-16 2025-10-01 アムジエン・インコーポレーテツド 失速及び終点検出を有するオートインジェクタ
IL275633B2 (en) 2018-01-17 2025-04-01 Amgen Inc Drug delivery mechanism
ES2993017T3 (en) 2018-03-07 2024-12-20 Amgen Inc Controlled dispense syringe
WO2019173785A1 (en) 2018-03-09 2019-09-12 Amgen Inc. Backflow prevention mechanism for drug delivery device
EP4321870B1 (de) 2018-03-13 2025-07-30 Amgen Inc. Verfahren zur herstellung von trypsinresistenten polypeptiden für massenspektrometrische analyse
IL277106B2 (en) 2018-03-13 2024-03-01 Amgen Inc Sequential digestion of polypeptides for mass spectrometric analysis
CN111788475A (zh) 2018-03-30 2020-10-16 安进公司 基于相机的药物容器检查
US11583633B2 (en) 2018-04-03 2023-02-21 Amgen Inc. Systems and methods for delayed drug delivery
US10835685B2 (en) 2018-05-30 2020-11-17 Amgen Inc. Thermal spring release mechanism for a drug delivery device
US11083840B2 (en) 2018-06-01 2021-08-10 Amgen Inc. Modular fluid path assemblies for drug delivery devices
AU2019288728A1 (en) 2018-06-23 2021-01-14 Genentech, Inc. Methods of treating lung cancer with a pd-1 axis binding antagonist, a platinum agent, and a topoisomerase ii inhibitor
BR112021000673A2 (pt) 2018-07-18 2021-04-20 Genentech, Inc. métodos para tratar um indivíduo com câncer de pulmão, kits, anticorpo anti-pd-l1 e composições
US12303677B2 (en) 2018-07-24 2025-05-20 Amgen Inc. Hybrid drug delivery devices with optional grip portion and related method of preparation
MX2021000749A (es) 2018-07-24 2021-03-29 Amgen Inc Dispositivos de suministro para administrar farmacos.
US12115360B2 (en) 2018-07-24 2024-10-15 Amgen Inc. Hybrid drug delivery devices with grip portion
US12042645B2 (en) 2018-07-24 2024-07-23 Amgen Inc. Delivery devices for administering drugs
WO2020023702A1 (en) 2018-07-25 2020-01-30 AskGene Pharma, Inc. Novel il-21 prodrugs and methods of use thereof
EP3829692A1 (de) 2018-07-31 2021-06-09 Amgen Inc. Flüssigkeitsweganordnungen für wirkstofffreisetzungsvorrichtung
IL280525B2 (en) 2018-08-08 2024-11-01 Genentech Inc Use of tryptophan derivatives and l-methionine for protein formulation
EP3836988A1 (de) 2018-08-17 2021-06-23 Amgen Inc. Aktivierungsmechanismus für eine wirkstofffreisetzungsvorrichtung
MX2021003213A (es) 2018-09-21 2021-05-12 Genentech Inc Metodos de diagnostico para cancer de mama triple negativo.
US20210346601A1 (en) 2018-09-24 2021-11-11 Amgen Inc. Interventional dosing systems and methods
EP3856283A1 (de) 2018-09-28 2021-08-04 Amgen Inc. Anordnung zur aktivierung des muskeldrahtvorschubs für eine medikamentenabgabevorrichtung
AU2019352616B2 (en) 2018-10-02 2024-10-10 Amgen Inc. Injection systems for drug delivery with internal force transmission
US12151089B2 (en) 2018-10-05 2024-11-26 Amgen Inc. Drug delivery device having dose indicator
SG11202103800RA (en) 2018-10-15 2021-05-28 Amgen Inc Drug delivery device having damping mechanism
JP2022504805A (ja) 2018-10-15 2022-01-13 アムジエン・インコーポレーテツド 薬物送達デバイスのプラットフォーム式組み立てプロセス
AU2019370159B2 (en) 2018-11-01 2025-05-29 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
US11213620B2 (en) 2018-11-01 2022-01-04 Amgen Inc. Drug delivery devices with partial drug delivery member retraction
TWI831847B (zh) 2018-11-01 2024-02-11 美商安進公司 部分針頭縮回之藥物遞送裝置及其操作方法
JP7769544B2 (ja) 2018-12-14 2025-11-13 アムジエン・インコーポレーテツド 勾配によるタンパク質濃度定量を伴う使用のためのシステム適合性方法
US11534547B2 (en) 2019-01-24 2022-12-27 Amgen Inc. Drug delivery systems and methods with pressure sensitive control
JP7483723B2 (ja) 2019-01-24 2024-05-15 アムジエン・インコーポレーテツド 背圧検知による薬剤送達のシステム及び方法
EP3924015A1 (de) 2019-02-12 2021-12-22 Amgen Inc. Dosiersysteme und -ansätze
ES2997201T3 (en) 2019-02-12 2025-02-14 Amgen Inc Take-home drug delivery system
WO2020167704A1 (en) 2019-02-12 2020-08-20 Amgen Inc. Continuous dosing systems and approaches
US20220062543A1 (en) 2019-02-12 2022-03-03 Amgen Inc. Continuous dosing systems and approaches
US20220072224A1 (en) 2019-02-12 2022-03-10 Amgen Inc. Continuous dosing systems and approaches
EP3923896A1 (de) 2019-02-12 2021-12-22 Amgen Inc. Systeme und ansätze zur rekonstitution von vorrichtungen zur medikamentenabgabe
EP4397977A3 (de) 2019-02-14 2024-09-11 Amgen Inc. Systeme und verfahren zur herstellung einer probe und durchführung eines echtzeittests der probe
CA3127817A1 (en) 2019-02-20 2020-08-27 Amgen Inc. Methods of determining protein stability
AU2020231509A1 (en) 2019-03-04 2021-08-19 Amgen Inc. In vivo reversibility of high molecular weight species
US12078701B2 (en) 2019-03-27 2024-09-03 Amgen Inc. Methods of fingerprinting therapeutic proteins via a two-dimensional (2D) nuclear magnetic resonance technique at natural abundance for formulated biopharmaceutical products
EP3952950A1 (de) 2019-04-08 2022-02-16 Amgen Inc. Automatische medikamentenabgabevorrichtung und behälter
CA3130603A1 (en) 2019-04-09 2020-10-15 Amgen Inc. Drug delivery device with smart grip
AU2020259327B2 (en) 2019-04-17 2025-07-24 Amgen Inc. Cassette for an autoinjector and related methods
JP7510952B2 (ja) 2019-04-24 2024-07-04 アムジエン・インコーポレーテツド シリンジ滅菌確認アセンブリ及び方法
EP3958925A1 (de) 2019-04-24 2022-03-02 Amgen Inc. Zubehörteile für injektor
US20220260584A1 (en) 2019-06-05 2022-08-18 Amgen Inc. Methods of identifying attributes of therapeutic proteins
WO2020252264A1 (en) 2019-06-12 2020-12-17 AskGene Pharma, Inc. Novel il-15 prodrugs and methods of use thereof
MX2021015571A (es) 2019-06-20 2022-01-24 Amgen Inc Dispositivo y metodo de administracion de farmacos habilitados para comunicacion inalambrica.
US12329944B2 (en) 2019-07-18 2025-06-17 Amgen Inc. Drug delivery device having pressurized vessel
US20220249778A1 (en) 2019-07-18 2022-08-11 Amgen Inc. Sealing arrangement for drug delivery device
MX2022001112A (es) 2019-08-01 2022-02-16 Amgen Inc Dispositivo de suministro de farmacos con medicion de la temperatura y metodo relacionado.
JP7608439B2 (ja) 2019-08-23 2025-01-06 アムジエン・インコーポレーテツド 構成可能な針シールド係合構成要素を備えた薬物送達デバイス及び関連方法
AU2020340905B2 (en) 2019-09-03 2025-12-04 Amgen Inc. Activatable injection device for drug delivery
WO2021046070A1 (en) 2019-09-03 2021-03-11 Amgen Inc. Injection device for drug delivery and packaging for the injection device
WO2021050494A1 (en) 2019-09-12 2021-03-18 Amgen Inc. Backflow prevention mechanism for drug delivery device
CA3150482A1 (en) 2019-09-16 2021-03-25 Amgen Inc. Method for external sterilization of drug delivery device
MX2022003292A (es) 2019-09-30 2022-04-12 Amgen Inc Dispositivo de administracion de farmacos y metodos de administracion de un farmaco.
US12102808B2 (en) 2019-09-30 2024-10-01 Amgen Inc. Drug delivery device
US20210093797A1 (en) 2019-09-30 2021-04-01 Amgen Inc. Drug delivery device
JP2022549349A (ja) 2019-09-30 2022-11-24 アムジエン・インコーポレーテツド 薬物送達デバイス
FI4037735T3 (fi) 2019-09-30 2025-11-25 Amgen Inc Lääkeaineen annostelulaite
AU2020357511B2 (en) 2019-09-30 2026-02-12 Amgen Inc. Drug delivery device
US20220362484A1 (en) 2019-10-07 2022-11-17 Amgen Inc. Drug delivery device
EP4041342A1 (de) 2019-10-07 2022-08-17 Amgen Inc. Nadeleinführmechanismus für eine arzneimittelabgabevorrichtung
WO2021071780A1 (en) 2019-10-07 2021-04-15 Amgen Inc. Drug delivery devices having light-activated ultrasonic fluid delivery
EP4041649A1 (de) * 2019-10-07 2022-08-17 Amgen Inc. Verpackungen für pharmazeutische produkte und verfahren zur montage
US20240100247A1 (en) 2019-10-08 2024-03-28 Amgen Inc. Needle insertion mechanism for drug delivery device
JP7757276B2 (ja) 2019-10-08 2025-10-21 アムジエン・インコーポレーテツド オートインジェクタ用のカセット及び関連方法
WO2021071694A1 (en) 2019-10-08 2021-04-15 Amgen Inc. Temperature indicator for drug delivery device
EP4041345B1 (de) 2019-10-08 2025-09-24 Amgen Inc. Arzneimittelabgabevorrichtung
CA3153518A1 (en) 2019-10-18 2021-04-22 Amgen Inc. Systems and approaches for drug delivery device reconstitution
WO2021076540A1 (en) 2019-10-18 2021-04-22 Amgen Inc. Drug delivery device and system
WO2021076824A1 (en) 2019-10-18 2021-04-22 Amgen Inc. Systems and approaches for drug delivery device reconstitution
EP4045110A2 (de) 2019-10-18 2022-08-24 Amgen Inc. Arzneimittelabgabevorrichtung und system
WO2021080828A1 (en) 2019-10-21 2021-04-29 Amgen Inc. Drug product container and drug delivery system
WO2021081161A1 (en) 2019-10-24 2021-04-29 Amgen Inc. Systems and components for drug delivery and components for preparation of the same
AU2020370370A1 (en) 2019-10-24 2022-05-05 Amgen Inc. Systems and approaches for drug delivery
WO2021080822A1 (en) 2019-10-24 2021-04-29 Amgen Inc. Systems and methods for drug delivery
WO2021081283A1 (en) 2019-10-24 2021-04-29 Amgen Inc. Drug delivery device
US20220387710A1 (en) 2019-10-24 2022-12-08 Amgen Inc. Drug delivery device and system
WO2021091749A1 (en) 2019-11-07 2021-05-14 Amgen Inc. Drug delivery system and method of use
EP4069340B1 (de) 2019-12-02 2025-10-15 Amgen Inc. Sperrmechanismus für eine wirkstofffreisetzungsvorrichtung
US20230347075A1 (en) 2019-12-05 2023-11-02 Amgen Inc. Flow restrictor for drug delivery device
EP4087864A1 (de) 2020-01-11 2022-11-16 Askgene Pharma, Inc. Neuartige maskierte cytokine und verfahren zu deren verwendung
CN114901330A (zh) 2020-01-13 2022-08-12 美国安进公司 针头护罩移除器、药物递送装置、以及相关方法
US12240652B2 (en) 2020-02-24 2025-03-04 Amgen Inc. Containers and systems for use during external sterilization of drug delivery devices
MX2022011458A (es) 2020-03-16 2022-10-07 Amgen Inc Conjuntos de deteccion de insercion de elementos de suministro de farmacos, dispositivos de suministro de farmacos y metodos relacionados.
CA3170808A1 (en) 2020-03-17 2021-09-23 Amgen Inc. Controlled dispense syringe
WO2021221845A1 (en) 2020-04-28 2021-11-04 Amgen Inc. Packaging label
WO2021236477A1 (en) 2020-05-22 2021-11-25 Amgen Inc. Storage system and method for storing and transporting medicament
CA3181820A1 (en) 2020-06-16 2021-12-23 Genentech, Inc. Methods and compositions for treating triple-negative breast cancer
JP2023540484A (ja) 2020-09-02 2023-09-25 アムジエン・インコーポレーテツド 薬剤保管カートン用の簡易開封装置
WO2022055779A1 (en) 2020-09-09 2022-03-17 Amgen Inc. Swallowable drug delivery devices
WO2022055761A1 (en) 2020-09-11 2022-03-17 Amgen Inc. Inline uv flow device for sterilizing flow cytometry sheath fluid
US20230349912A1 (en) 2020-09-18 2023-11-02 Amgen Inc. Methods of processing a sample for peptide mapping analysis
EP4225398A1 (de) 2020-10-12 2023-08-16 Amgen Inc. Langzeit-medikamentenaufbewahrungsvorrichtung und -verfahren
EP4240451A1 (de) 2020-11-04 2023-09-13 Amgen Inc. Arzneimittelabgabevorrichtungsanordnung und zubehör für arzneimittelabgabevorrichtung
US20230277778A1 (en) 2020-11-04 2023-09-07 Amgen Inc. Drug delivery device assembly and accessory for drug delivery device
WO2022098590A1 (en) 2020-11-04 2022-05-12 Amgen Inc. Drug delivery device assembly and accessory for drug delivery device
JP2023549083A (ja) 2020-11-04 2023-11-22 アムジエン・インコーポレーテツド 薬物送達デバイスアセンブリ及び薬物送達デバイス用アクセサリ
US20240010672A1 (en) 2020-11-05 2024-01-11 Amgen Inc. Materials and methods for protein processing
EP4288198A1 (de) 2021-02-03 2023-12-13 Amgen Inc. Automatisierte rekonstitution mit hohem durchsatz eines lyophilisierten arzneimittelprodukts
WO2022169724A1 (en) 2021-02-03 2022-08-11 Amgen Inc. Coaxial needle adapter and guide bracket for robotic liquid handling platform
WO2022169726A1 (en) 2021-02-03 2022-08-11 Amgen Inc. Systems and approaches for drug processing
CA3211462A1 (en) 2021-03-08 2022-09-15 Amgen Inc. Manufacturing process for hollow plunger rod
CN116963793A (zh) 2021-03-10 2023-10-27 美国安进公司 药物递送装置、用于药物递送装置的子组件、注射器保持器以及组装方法
MX2023010441A (es) 2021-03-10 2023-09-12 Amgen Inc Dispositivo de administracion de farmacos que tiene una tapa extraible.
US20220288324A1 (en) 2021-03-10 2022-09-15 Amgen Inc. Drug delivery device
BR112023019565A2 (pt) 2021-03-25 2023-11-14 Amgen Inc Dispositivo de administração de fármacos
WO2022212227A1 (en) 2021-03-31 2022-10-06 Amgen Inc. Sound-detection based injection time measurement system for drug delivery devices
MX2023011513A (es) 2021-04-22 2023-10-05 Amgen Inc Metodos y sistemas para la evaluacion automatizada de la calidad de jeringas.
MX2023012610A (es) 2021-04-28 2023-11-03 Amgen Inc Sistemas para el tratamiento ambulatorio de un paciente y metodos relacionados.
US20240257936A1 (en) 2021-05-17 2024-08-01 Amgen Inc. Feedback system and method for a drug product
CA3217207A1 (en) 2021-05-21 2022-11-24 Amgen Inc. Method of optimizing a filling recipe for a drug container
EP4348141A1 (de) 2021-06-01 2024-04-10 Amgen Inc. Lyophilisierungssystem
EP4351682A1 (de) 2021-06-08 2024-04-17 Amgen Inc. Arzneimittelabgabevorrichtungen, fingergriffelemente und zugehörige verfahren
WO2022266272A1 (en) 2021-06-17 2022-12-22 Amgen Inc. Drug delivery device having shock absorber
TW202313136A (zh) 2021-06-23 2023-04-01 美商安進公司 注射器、組件和製造方法
WO2023278125A1 (en) 2021-06-28 2023-01-05 Amgen Inc. Safety device for drug delivery system
WO2023287562A1 (en) 2021-07-16 2023-01-19 Amgen Inc. Systems and approaches for drug processing single-use hardware
CN117999106A (zh) 2021-09-29 2024-05-07 美国安进公司 用于预填充式注射器中的柱塞-塞子深度测量的设备、系统和方法
EP4412681A1 (de) 2021-10-06 2024-08-14 Amgen Inc. Stossaktivierte rückhaltefunktion für eine arzneimittelabgabevorrichtung
WO2023059672A1 (en) 2021-10-06 2023-04-13 Amgen Inc. Impact activated brake feature for drug delivery device
WO2023064119A1 (en) 2021-10-11 2023-04-20 Amgen Inc. Characterization apparatus for drug delivery devices or subcomponents thereof
EP4427113A1 (de) 2021-11-05 2024-09-11 Amgen Inc. Arzneimittelabgabevorrichtungen, komponenten zur verwendung in arzneimittelabgabevorrichtungen
TW202325853A (zh) 2021-11-09 2023-07-01 美商安進公司 治療性蛋白之生產
JP2024540611A (ja) 2021-11-29 2024-10-31 アムジエン・インコーポレーテツド プランジャロッド除去力に関する方法及び固定具
MX2024006561A (es) 2021-12-03 2024-06-12 Amgen Inc Colocacion de tapon en una jeringa.
IL314557A (en) 2022-03-11 2024-09-01 Amgen Inc Automatic injector with adjustable depth
US20250186681A1 (en) 2022-04-06 2025-06-12 Amgen Inc. Packaging for drug delivery device
CA3263439A1 (en) 2022-08-04 2024-02-08 Novartis Pharma Ag IL-15 INHIBITORS USEFUL FOR THE TREATMENT OF ATOPIC DERMATITIS
WO2024040020A1 (en) 2022-08-15 2024-02-22 Absci Corporation Quantitative affinity activity specific cell enrichment
US20260041853A1 (en) 2022-08-18 2026-02-12 Amgen Inc. Needle shield assembly for a syringe
AU2023326190A1 (en) 2022-08-18 2025-01-23 Amgen Inc. Needle shield for syringe
IL318143A (en) 2022-08-30 2025-03-01 Amgen Inc System and method for limiting sub-visible particles in a syringe
AR132559A1 (es) 2023-05-01 2025-07-16 Amgen Inc Analizadores biológicos portátiles configurables para la identificación de productos biológicos basándose en la espectroscopia raman usando inteligencia artificial conjunta
CN118894934A (zh) 2023-05-05 2024-11-05 北京智仁美博生物科技有限公司 抗人il-15的抗体及其用途
CN121311767A (zh) 2023-06-14 2026-01-09 百时美施贵宝公司 糖蛋白的近实时唾液酸定量
WO2025019224A1 (en) 2023-07-14 2025-01-23 Amgen Inc. Monitoring systems and methods for injection devices
AU2024353933A1 (en) 2023-09-26 2026-02-12 Amgen Inc. Packaging systems for medical devices
WO2025101602A1 (en) 2023-11-07 2025-05-15 Amgen Inc. Methods of analyzing amino acid content of a therapeutic protein
CN117209605B (zh) * 2023-11-09 2024-01-30 北京百普赛斯生物科技股份有限公司 特异性结合il-15的抗体及其应用
TW202543890A (zh) 2023-11-28 2025-11-16 美商安進公司 用於對部件進行箔包裝的自動化系統及方法
WO2025136894A1 (en) 2023-12-18 2025-06-26 Amgen Inc. Ampoule adapter and method of use
WO2025136766A1 (en) 2023-12-20 2025-06-26 Amgen Inc. Packaging for drug administration
WO2025144700A1 (en) 2023-12-27 2025-07-03 Absci Corporation Nanobody library screening using bacterial surface display
US20250269119A1 (en) 2024-02-28 2025-08-28 Amgen Inc. Drug delivery device
AR134332A1 (es) 2024-02-29 2026-01-07 Amgen Inc Sistemas de embajale sostenibles y modulares para envases de uso farmacéutico
WO2025213011A1 (en) 2024-04-05 2025-10-09 Amgen Inc. Method of assessing stopper movement in a drug delivery device
CN120818052A (zh) * 2024-04-12 2025-10-21 信达生物制药(苏州)有限公司 抗il-15抗体以及其用途
WO2025222117A1 (en) 2024-04-19 2025-10-23 Amgen Inc. Drug delivery device
WO2025255028A1 (en) 2024-06-03 2025-12-11 Amgen Inc. High-throughput liquid chromatography-mass spectrometry-based peptide mapping
WO2026030152A1 (en) 2024-07-29 2026-02-05 Amgen Inc. System and method for assessing transferability of a fill recipe

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2087997T3 (es) * 1990-01-12 1996-08-01 Cell Genesys Inc Generacion de anticuerpos xenogenicos.
US6255458B1 (en) * 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5574138A (en) * 1993-03-08 1996-11-12 Immunex Corporation Epithelium-derived T-cell factor
US5591630A (en) * 1994-05-06 1997-01-07 Immunex Corporation Monoclonal antibodies that bind interleukin-15 receptors
US5795966A (en) * 1995-02-22 1998-08-18 Immunex Corp Antagonists of interleukin-15
ATE221784T1 (de) * 1995-04-02 2002-08-15 Chugai Pharmaceutical Co Ltd Arzneimittel zur heilung von thrombozytopenie
CA2219486A1 (en) 1995-04-28 1996-10-31 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5660824A (en) * 1995-05-24 1997-08-26 Grabstein; Kenneth H. Muscle trophic factor
WO1997010354A1 (fr) * 1995-09-11 1997-03-20 Kyowa Hakko Kogyo Co., Ltd. Anticorps de la chaine alpha du recepteur de l'interleukine 5 humaine
US6001973A (en) * 1996-04-26 1999-12-14 Beth Israel Deaconess Medical Center Antagonists of interleukin-15
EP0932417B1 (de) * 1996-10-17 2003-03-05 Immunomedics, Inc. Nichtantigenes toxinkonjugat und fusionsprotein eines internalisierendes rezeptorsystems
EP1273304B2 (de) 1997-02-21 2009-07-15 Amgen Inc. Verwendung von Interleukin-15
DE69841452D1 (de) * 1997-02-28 2010-03-04 Kyowa Hakko Kirin Co Ltd Humanes Chromosomfragment und ein Vektor, der dies enthält
GB9814892D0 (en) 1998-07-10 1998-09-09 Kennedy Rheumatology Inst Treatment of celiac disease
AU6689700A (en) 1999-07-06 2001-01-22 Silvia Bulfone-Paus Method of treating psoriasis with il-15 antagonist
PL217752B1 (pl) 2001-08-23 2014-08-29 Genmab As Izolowane ludzkie przeciwciało monoklonalne wobec IL-15 lub jego fragment wiążący antygen i związane z nimi hybrydoma, kompozycja farmaceutyczna oraz zastosowania medyczne

Also Published As

Publication number Publication date
PL217752B1 (pl) 2014-08-29
NO20040752L (no) 2004-04-24
JP2005503151A (ja) 2005-02-03
CY1112447T1 (el) 2015-12-09
EA014802B1 (ru) 2011-02-28
EA200400345A1 (ru) 2004-12-30
PT1425389E (pt) 2012-02-07
AU2002332628B2 (en) 2007-07-26
HK1066828A1 (en) 2005-04-01
WO2003017935A2 (en) 2003-03-06
DK1425389T3 (da) 2012-01-30
US7153507B2 (en) 2006-12-26
ES2375271T3 (es) 2012-02-28
NO333152B1 (no) 2013-03-18
IL160358A0 (en) 2004-07-25
NZ531211A (en) 2007-04-27
KR20040047796A (ko) 2004-06-05
EP1425389A2 (de) 2004-06-09
WO2003017935A9 (en) 2003-04-10
EP1425389B1 (de) 2011-11-02
JP2009256354A (ja) 2009-11-05
CA2456648C (en) 2011-08-16
JP4359503B2 (ja) 2009-11-04
YU15104A (sh) 2006-08-17
IL160358A (en) 2010-12-30
EP1425389A4 (de) 2007-08-01
RS51829B (sr) 2012-02-29
US20030138421A1 (en) 2003-07-24
CA2456648A1 (en) 2003-03-06
SI1425389T1 (sl) 2012-02-29
KR100911951B1 (ko) 2009-08-13
WO2003017935A3 (en) 2003-08-14
CN100557018C (zh) 2009-11-04
CN1571836A (zh) 2005-01-26
BR0212136A (pt) 2004-12-07
ZA200401144B (en) 2005-05-12
PL371946A1 (en) 2005-07-11
HU229776B1 (hu) 2014-07-28
MXPA04001486A (es) 2004-10-27
HUP0402653A2 (hu) 2005-03-29
HUP0402653A3 (en) 2010-01-28

Similar Documents

Publication Publication Date Title
ATE531390T1 (de) Interleukin-15-(il-15-)spezifische menschliche antikörper
LTPA2021514I1 (de)
TW200500378A (en) Human antibodies specific for interleukin 15 (IL-15)
AU2003303237A8 (en) Human monoclonal antibodies to epidermal growth factor receptor (egfr)
EP1590364A4 (de) Humane monoklonale antikörper gegen interleukin 8 (il-8)
DE60037896D1 (de) Menschliche antikörper gegen her2/neu
DK1210374T3 (da) Humane, monoklonale antistoffer over for prostataspecifikt membranantigen
EA200500835A1 (ru) Человеческие моноклональные антитела против cd25
WO2003064606A3 (en) Human monoclonal antibodies to prostate specific membrane antigen (psma)

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 1425389

Country of ref document: EP